Clinic
CGH Hospital, LTD.
CGH Hospital, LTD. was paid $1.67M by Medicaid between Jan 2018 and Sep 2021, across 122 billing codes. Its largest line is A4216, Sterile water, saline and/or dextrose, diluent/flush, 10 ml — 21% of everything it billed.
33Billing provider infoCGH HOSPITAL, LTD.
CORAL GABLES, FL 33134
CORAL GABLES, FL 33134
33aNPI1649200601assigned 07/04/2006
33bProvider typeClinic/Center
28Total paid$1.67M
24GClaims151,531
24DCodes billed122
24AFirst – last monthJan 2018 – Sep 2021
Compared with peers
Next to other Clinic/Center providers in Florida
Rank by total paid#33 of 349
Median peer was paid$95K
This provider vs. median18×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 28,751 | $365K | |
| 2019 | 57,066 | $561K | |
| 2020 | 35,982 | $428K | |
| 2021 | 29,732 | $312K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 21% | 2,908 | 1,850 | $347K |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.1% | 3,658 | 2,469 | $152K |
| 80053 | Comprehensive metabolic panel | 5.6% | 6,160 | 4,554 | $94K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.5% | 4,868 | 4,006 | $92K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.4% | 4,131 | 3,204 | $90K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.0% | 3,930 | 521 | $67K |
| S0028 | Injection, famotidine, 20 mg | 3.5% | 1,003 | 786 | $58K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2.8% | 1,814 | 1,450 | $46K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 2.5% | 1,703 | 193 | $42K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.5% | 3,038 | 1,944 | $41K |
| J3490 | Unclassified drugs | 2.3% | 195 | 79 | $39K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.3% | 3,229 | 2,593 | $38K |
110 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.2% | 1,495 | $37K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 1,665 | $36K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.8% | 2,892 | $30K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 840 | $30K |
| 82962 | 1.6% | 3,909 | $27K | |
| 81025 | 1.3% | 2,220 | $22K | |
| A9270 | Non-covered item or service | 1.3% | 3,966 | $22K |
| G0378 | Hospital observation service, per hour | 1.2% | 4,411 | $20K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 9,247 | $20K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 793 | $18K |
| 71045 | Radiologic examination, chest; single view | 1.0% | 4,692 | $17K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 1,087 | $17K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 341 | $17K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 437 | $14K |
| 81001 | <1% | 3,391 | $14K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,543 | $12K |
| 81003 | <1% | 2,372 | $12K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,792 | $10K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 311 | $9K |
| 85610 | <1% | 4,384 | $9K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,149 | $9K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,250 | $9K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 806 | $8K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,004 | $8K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,041 | $7K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 798 | $7K |
| 84484 | <1% | 3,918 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,105 | $6K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,288 | $6K |
| 85730 | <1% | 3,842 | $6K | |
| 96376 | <1% | 1,539 | $6K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,984 | $6K |
| 97124 | <1% | 293 | $6K | |
| 97162 | <1% | 413 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 299 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 926 | $4K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 215 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,269 | $3K |
| 72131 | <1% | 309 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,784 | $3K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 440 | $3K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 178 | $3K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 550 | $3K |
| 87070 | <1% | 380 | $2K | |
| 87040 | <1% | 1,233 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 352 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,861 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,339 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,341 | $2K |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 121 | $2K |
| A4217 | Sterile water/saline, 500 ml | <1% | 381 | $2K |
| 94664 | <1% | 469 | $2K | |
| 82550 | <1% | 2,222 | $2K | |
| 83880 | <1% | 886 | $2K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 45 | $1K |
| 86850 | <1% | 805 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 254 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 514 | $1K |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 239 | $1K |
| 83690 | <1% | 1,527 | $1K | |
| 86900 | <1% | 831 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 267 | $994.97 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 19 | $988.67 |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 42 | $946.49 |
| 93970 | <1% | 147 | $916.99 | |
| 76830 | Ultrasound, transvaginal | <1% | 28 | $883.44 |
| 86901 | <1% | 832 | $846.91 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 258 | $841.59 |
| 76801 | <1% | 30 | $710.82 | |
| 73030 | <1% | 23 | $559.94 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 934 | $532.92 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 88 | $526.19 |
| 83605 | <1% | 670 | $498.55 | |
| 82805 | <1% | 102 | $493.32 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 180 | $451.56 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 44 | $408.99 |
| 87186 | <1% | 422 | $304.62 | |
| 87077 | <1% | 408 | $304.54 | |
| 71250 | <1% | 87 | $283.52 | |
| 84702 | <1% | 251 | $279.30 | |
| 85379 | <1% | 462 | $276.92 | |
| 73630 | <1% | 20 | $173.87 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 28 | $172.94 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 554 | $141.55 |
| 97166 | <1% | 16 | $122.96 | |
| 80076 | <1% | 137 | $119.06 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 97 | $115.48 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 435 | $92.37 |
| 84703 | <1% | 191 | $66.59 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 44 | $51.96 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 44 | $20.41 |
| 80061 | Lipid panel | <1% | 26 | $6.80 |
| 87430 | <1% | 134 | $6.11 | |
| J1815 | Injection, insulin, per 5 units | <1% | 93 | $4.63 |
| 86140 | <1% | 115 | $3.00 | |
| 99001 | 0% | 149 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 91 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 64 | $0.00 |
| J0285 | Injection, amphotericin b, 50 mg | 0% | 15 | $0.00 |
| 73562 | 0% | 19 | $0.00 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 58 | $0.00 |
| 90715 | 0% | 35 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 28 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 50 | $0.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 33 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 17 | $0.00 |
| 88304 | 0% | 43 | $0.00 | |
| C1781 | Mesh (implantable) | 0% | 17 | $0.00 |
| 82150 | 0% | 36 | $0.00 | |
| 83735 | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialARMIN, CRAIG (VP OF GOVT PROGRAMS, TENET)
| Provider | Location | Paid |
|---|---|---|
| Lifemark Hospitals of Florida, INC. | Hialeah, FL | $7.11M |
| North Shore Medical Center, INC. | Miami, FL | $4.42M |
| Hialeah Hospital INC. | Hialeah, FL | $3.62M |
| North Shore Medical Center, INC. | Lauderdale Lakes, FL | $2.52M |
| VHS West Suburban Medical Center INC | Oak Park, IL | $1.46M |
| VHS Westlake Hospital INC | Melrose Park, IL | $326K |
| Tenet Healthsystem ST. Christopher's Hospital for Children, LLC | Philadelphia, PA | $22K |
| FMC Hospital, LTD. | Lauderdale Lakes, FL | $4K |
| San Dimas Community Hospital, INC. | San Dimas, CA | $963.01 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.